Biotech Daily: Dr Boreham's Crucible: Arovella
By Tim Borham
Fickle fashion trends don’t just apply to apparel: a hot area two years ago, the cell therapies sector is struggling to retain investor interest amid hyped-up expectations, clinical setbacks and high development and manufacturing costs.
